MediciNova, Inc. 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Its primary programs are MN-166 (ibudilast) for neurological disorders and addiction, and MN-001 (tipelukast) for fibrotic diseases. Additional pipeline programs include MN-221 and MN-029. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2018.
Financial Position and Results
| Metric | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patents expense | $1.4 million | $3.0 million |
| General and administrative expense | $2.0 million | $5.0 million |
| Total operating expenses | $3.4 million | $8.1 million |
| Operating loss | $3.4 million | $8.1 million |
| Net loss | $3.1 million | $7.7 million |
| Net loss per share | $0.08 | $0.19 |
Interest income was $250,231 for the quarter and $381,576 for the six-month period, partially offsetting operating losses. No meaningful profitability or operating margin was reported because the company had no revenue and incurred operating losses.
At June 30, 2018, cash and cash equivalents were $64.2 million, compared with $28.0 million at December 31, 2017. Working capital was $63.0 million. Total liabilities were $3.5 million, including $1.7 million of long-term deferred revenue; the filing reports no debt financing. Goodwill was $9.6 million and in-process research and development was $4.8 million.
For the six months ended June 30, 2018, operating cash usage was $5.7 million. Investing activities provided $0.6 million, primarily from proceeds from dissolution of the Zhejiang Sunmy joint venture. Financing activities provided $41.3 million, principally from equity issuance and warrant exercises.
Material Changes Versus Prior Comparable Period
- Six-month research, development and patents expense increased to $3.0 million from $1.8 million, driven by higher MN-166 and MN-001 clinical research costs and increased performance-based stock compensation.
- Six-month general and administrative expense increased to $5.0 million from $4.0 million, primarily due to higher performance-based stock compensation.
- Six-month net loss increased to $7.7 million from $5.8 million; loss per share increased to $0.19 from $0.17.
- Six-month operating cash use increased to $5.7 million from $4.0 million.
- The company raised approximately $38.5 million of net proceeds in a February 2018 public offering and received $2.4 million from exercise of 750,000 warrants. Shares outstanding increased to 41.9 million from 36.5 million at year-end 2017.
- Stock-based compensation increased to approximately $3.4 million from $1.9 million for the six-month period.
- The Zhejiang Sunmy joint venture was dissolved, and the company received approximately $0.6 million in liquidation proceeds. No investment remained on the June 30, 2018 balance sheet.
Guidance, Outlook, Risks and Unusual Items
Management expects research and development costs to increase throughout 2018 as development programs progress. The company expects substantial net losses for the next several years and has an accumulated deficit of $349.1 million.
Management stated that available cash and working capital were sufficient to fund operations at least through December 31, 2019, while cautioning that resources may not be sufficient to conduct all planned research and development programs.
The Kissei collaboration has an uncompleted second study related to MN-221. No collaboration revenue was recognized during the quarter or six-month period, and the remaining deferred revenue of $1.7 million is expected to be recognized when the performance obligation is satisfied, which management expects to occur after 2018.
Key risks include the need for additional capital or future product revenue, failure or delay in clinical trials, inability to obtain regulatory approvals, insufficient efficacy or safety, reliance on MN-166 and MN-001, dependence on third parties, loss of licensed rights, competition, intellectual property disputes, manufacturing constraints, reimbursement and market acceptance risks, and the loss of key personnel. The filing states that there were no material changes to the risk factors disclosed in the 2017 Form 10-K.
The company reported no material legal proceedings, no material changes in internal control over financial reporting, and no off-balance-sheet arrangements. Disclosure controls and procedures were assessed as effective at the reasonable-assurance level.
Important Facts for Investors to Verify
- Whether the reported $64.2 million cash balance and stated funding horizon remain adequate relative to expected clinical development spending.
- The enrollment, timing, cost and outcomes of MN-166 and MN-001 clinical trials, particularly the progressive MS, ALS, NASH and IPF programs.
- Whether and when the remaining Kissei study will begin and whether the $1.7 million deferred revenue will be recognized.
- The company’s ability to secure non-dilutive funding, strategic partnerships or additional equity capital without substantial dilution.
- The potential impact of continued losses, stock-based compensation and outstanding options covering approximately 6.6 million shares.
- Regulatory, clinical, safety, intellectual property and commercialization risks affecting the product pipeline.